Arndt Vogel, Prof. Dr.
Hannover Medical School
3
3
2
N/A
0
2
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Salah-Eddin Al-Batran, Prof. Dr.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Shared therapeutic areas:
Worked with same sponsors:
Salah-Eddin Al-Batran, Prof. Dr.
Institut für Klinische Krebsforschung IKF GmbH
Shared therapeutic areas:
Worked with same sponsors:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Tim F Greten, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jacek Pinski, MD
University of Southern California
Shared therapeutic areas:
Kangshun Zhu, Dr.
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Dan Zandberg, MD
UPMC Hillman Cancer Center
Shared therapeutic areas:
Weijun Wei, Ph.D. & M.D.
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shared therapeutic areas:
Saleh K Saleh, MD
Minia University
Shared therapeutic areas:
Renuka Iyer, MD
Roswell Park Cancer Institute
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
All 3 trials loaded